An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

NCT04950764 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Biliary Cholangitis
Compensated Cirrhosis
Hepatic Impairment

Interventions

DRUG: Seladelpar

Sponsor

Gilead Sciences